 "Laurus Labs launches generic Lyrica in US to treat neuropathic conditions")
Hyderbad-based Laurus Labs Ltd along with its exclusive distribution partner Rising Pharmaceuticals today announced the launch of generic version of Lyrica (pregabalin) capsules in the US market.
Pregabalin capsules had approximately $5,497 million US sales in FY19, the company said quoting the intercontinental marketing statistics (IMS) Health data. The drug is indicated for management of neuropathic pain caused by different health conditions.
"We are happy to develop and manufacture the Pregabalin capsules for our distribution partner Rising Pharmaceuticals in US. As we move forward in the finished dosage form (FDF) segment backed by our strong active pharmaceutical ingredient (API) manufacturing facilities, we will strengthen our portfolio for long term and sustainable growth by leveraging our partnerships and global presence," Laurus Labs CEO Satyanarayana Chava said.
According to Rising Pharmaceuticals CEO Vimal Kavuru, the introduction of Pregabalin capsules is one of the largest launches for the company this year and it will provide a cost-effective treatment option for people living with neuropathic pain conditions.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%